Agile Therapeutics (NASDAQ:AGRX) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
This table compares Agile Therapeutics and IDEAYA Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Agile Therapeutics and IDEAYA Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Agile Therapeutics||N/A||N/A||-$18.61 million||($0.38)||-7.26|
|IDEAYA Biosciences||N/A||N/A||-$41.97 million||($3.36)||-3.94|
Agile Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for Agile Therapeutics and IDEAYA Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agile Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 135.51%. IDEAYA Biosciences has a consensus price target of $19.67, indicating a potential upside of 48.43%. Given Agile Therapeutics’ higher possible upside, analysts plainly believe Agile Therapeutics is more favorable than IDEAYA Biosciences.
Insider and Institutional Ownership
38.1% of Agile Therapeutics shares are owned by institutional investors. Comparatively, 49.9% of IDEAYA Biosciences shares are owned by institutional investors. 4.4% of Agile Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
IDEAYA Biosciences beats Agile Therapeutics on 5 of the 9 factors compared between the two stocks.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.